NeoGenomics, Inc. (NEO) Market Cap & Valuation Ratios
NeoGenomics, Inc. (NEO) has a market cap of $2.1B and a price-to-sales ratio of 2.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NEONeoGenomics, Inc.Follow NEO — free
—
Price chart with a free account
- Market cap
- 2.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Peers
diagnostics & research · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NEO | 2.1 | — | 3.1 | — | -0.3% | +11% | -9% | -7% |
| SHC | 5.2 | 31.8 | 5.7 | 13.0 | 2.2% | +8% | 34% | 10% |
| BLLN | 5.1 | 193.9 | 11.6 | 92.1 | 0.7% | +90% | 11% | 54% |
| ADPT | 4.1 | — | 13.2 | — | -0.6% | +50% | -12% | -13% |
| VCYT | 3.9 | 34.2 | 6.3 | 28.1 | 4.3% | +17% | 19% | 10% |
| CDNA | 3.6 | 33.4 | 7.0 | 26.2 | 1.0% | +34% | 24% | 67% |
| PSNL | 1.7 | — | 21.2 | — | -6.0% | -13% | -164% | -82% |
| WGS | 1.7 | — | 3.6 | — | -4.5% | +25% | -20% | -35% |
| OPK | 1.2 | — | 2.1 | 30.5 | -11.0% | -11% | -8% | -4% |
| LMRI | 1.1 | — | — | — | — | — | 9% | — |
| CSTL | 1.0 | — | 2.1 | — | -0.0% | +3% | -9% | -8% |
| Median of these 10 | 33.8 | 6.3 | 28.1 | -0.0% | +17% | 0.3% | -4% |
; EV/Sales 3.1 vs. 6.3.
Growth vs. price
each dot a company · hover or tap for valuesNEO and ADPT and PSNL and WGS and OPK and LMRI and CSTL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
NeoGenomics, Inc. — questions
- What is NeoGenomics, Inc.'s market cap?
- $2.1B.
- What is NeoGenomics, Inc.'s price-to-sales ratio?
- 2.8.
Every figure on this page comes from NeoGenomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.